TECH vs BMRN vs MDGL
161 measures in 16 categories, one definition each, computed from filings and market data.
BMRN47.5
BioMarin Pharmaceutical Inc.
Healthcare · Biotechnology
$54.68 −2.44%$10.6B mkt cap
Score DNA
MDGL40.3
Madrigal Pharmaceuticals, Inc.
Healthcare · Biotechnology
$449.74 −2.19%$10.4B mkt cap
Score DNA
Price, rebased to 100 three years ago
TECH BMRN MDGL · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | TECH | BMRN | MDGL |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 0 | 0 | 0 |
| Last Congress purchase | — | — | — |
| 13F net change in holders | +15 | +6 | — |
| ETFs adding shares, 30d | 524 | 384 | 213 |
| ETFs trimming, 30d | 453 | 291 | 147 |
| Net ETF funds, 30d | +71 | +93 | +66 |
Valuation
16 measures| Measure | TECH | BMRN | MDGL |
|---|---|---|---|
| P/E (TTM) | 62.6x
81st
|
145.1x
100th
|
— |
| PEG (P/E ÷ 3-yr EPS CAGR) | — | — | — |
| Price / sales | 9.4x
54th
|
3.1x
16th
|
8.1x
46th
|
| Price / book | 5.4x
60th
|
1.7x
13th
|
19.8x
90th
|
| Price / tangible book | 13.4x
83rd
|
14.1x
84th
|
30.3x
93rd
|
| Price / free cash flow | 43.2x
73rd
|
14.3x
29th
|
— |
| Price / operating cash flow | 39.0x
73rd
|
12.3x
24th
|
— |
| Enterprise value | $11.4B
88th
|
$13.9B
89th
|
$9.9B
86th
|
| EV / sales | 9.4x
57th
|
4.1x
29th
|
7.7x
49th
|
| EV / EBITDA | 33.2x
71st
|
36.1x
73rd
|
— |
| EV / EBIT | 46.3x
78th
|
59.8x
82nd
|
— |
| EV / free cash flow | 43.3x
76th
|
18.8x
41st
|
— |
| Earnings yield | 1.6%
78th
|
0.7%
73rd
|
-3.1%
60th
|
| FCF yield | 2.3%
78th
|
7.0%
91st
|
-2.0%
62nd
|
| Operating cash flow yield | 2.6%
78th
|
8.1%
93rd
|
-1.9%
62nd
|
| Graham number (per share) | $18.71
53rd
|
$16.59
44th
|
— |
Profitability (TTM)
12 measures| Measure | TECH | BMRN | MDGL |
|---|---|---|---|
| Gross margin | 65.8%
21st
|
75.5%
29th
|
91.5%
63rd
|
| EBITDA margin | 28.3%
83rd
|
11.3%
75th
|
-22.7%
56th
|
| Operating margin | 20.7%
80th
|
8.0%
74th
|
-25.1%
54th
|
| EBIT margin | 20.3%
82nd
|
6.8%
73rd
|
-22.9%
57th
|
| Net margin | 15.0%
79th
|
2.1%
73rd
|
-25.3%
57th
|
| NOPAT margin | 15.7%
79th
|
3.9%
72nd
|
-19.9%
56th
|
| FCF margin | 21.7%
83rd
|
21.7%
84th
|
-16.1%
56th
|
| Operating cash flow margin | 24.0%
82nd
|
25.2%
84th
|
-15.4%
54th
|
| R&D / revenue | 7.8%
7th
|
29.0%
30th
|
38.2%
42nd
|
| SG&A / revenue | 37.2%
29th
|
50.6%
37th
|
78.4%
59th
|
| Stock comp / revenue | 3.4%
10th
|
6.3%
20th
|
7.4%
25th
|
| Effective tax rate | 24.4%
95th
|
51.1%
100th
|
21.0%
19th
|
Returns on capital
11 measures| Measure | TECH | BMRN | MDGL |
|---|---|---|---|
| ROE (on average equity) | 9.0%
76th
|
1.2%
71st
|
-53.3%
28th
|
| ROA | 6.9%
78th
|
0.8%
73rd
|
-28.8%
34th
|
| ROIC | 8.9%
53rd
|
1.4%
49th
|
-778.9%
3rd
|
| ROCE | 9.8%
78th
|
2.3%
73rd
|
-33.7%
32nd
|
| Return on tangible assets | 9.4%
79th
|
2.4%
73rd
|
-26.0%
35th
|
| Cash ROIC (OCF / invested capital) | 13.7%
67th
|
8.9%
63rd
|
-604.2%
3rd
|
| Gross profitability (GP / assets) | 29.8%
52nd
|
22.0%
46th
|
94.4%
96th
|
| ROIC, 3-yr average | 5.8%
74th
|
3.1%
70th
|
— |
| ROIC, 5-yr average | 9.6%
62nd
|
4.1%
59th
|
-367.7%
4th
|
| ROE, 5-yr average | 10.2%
90th
|
4.0%
86th
|
-157.4%
7th
|
| Incremental ROIC | 391.6%
96th
|
-4.8%
40th
|
-62.4%
17th
|
Growth
17 measures| Measure | TECH | BMRN | MDGL |
|---|---|---|---|
| Revenue growth (TTM YoY) | -0.4%
32nd
|
11.2%
42nd
|
149.0%
82nd
|
| Revenue growth (QoQ) | 3.1%
28th
|
29.2%
71st
|
17.0%
51st
|
| Revenue CAGR, 3 yr | 2.2%
27th
|
15.1%
38th
|
— |
| Revenue CAGR, 5 yr | 5.5%
29th
|
12.2%
39th
|
— |
| Gross profit CAGR, 3 yr | 1.3%
29th
|
14.3%
43rd
|
— |
| Operating income CAGR, 3 yr | -5.5%
18th
|
39.3%
65th
|
— |
| Net income growth (TTM YoY) | 147.8%
70th
|
-88.9%
4th
|
— |
| Net income CAGR, 3 yr | -13.9%
8th
|
-10.0%
15th
|
— |
| EPS growth (TTM YoY) | 145.8%
70th
|
-88.8%
4th
|
— |
| EPS CAGR, 3 yr | -13.0%
8th
|
-9.8%
15th
|
— |
| EPS CAGR, 5 yr | 6.2%
27th
|
-39.2%
0th
|
— |
| FCF growth (TTM YoY) | 2.6%
32nd
|
6.8%
36th
|
— |
| FCF CAGR, 3 yr | 6.8%
31st
|
162.3%
100th
|
— |
| Operating cash flow CAGR, 3 yr | 4.7%
19th
|
74.5%
100th
|
— |
| Book value CAGR, 3 yr | 3.4%
59th
|
9.9%
68th
|
47.0%
94th
|
| Dividend CAGR, 3 yr | 0.7% | — | — |
| Sustainable growth rate | 6.6%
14th
|
1.2%
0th
|
— |
Margin history & stability
7 measures| Measure | TECH | BMRN | MDGL |
|---|---|---|---|
| Gross margin, 3-yr average | 65.7%
30th
|
78.3%
43rd
|
94.1%
80th
|
| Operating margin, 3-yr average | 15.6%
86th
|
14.4%
86th
|
-1,236.0%
14th
|
| Net margin, 3-yr average | 11.8%
82nd
|
11.2%
81st
|
-1,189.0%
15th
|
| FCF margin, 3-yr average | 21.0%
89th
|
17.5%
87th
|
-1,063.3%
16th
|
| Revenue stability (0-1) | 0.88
78th
|
0.95
89th
|
0.64
52nd
|
| Earnings stability (0-1) | 0.11
17th
|
0.09
12th
|
0.15
23rd
|
| Margin stability (0-1) | 0.98
89th
|
0.95
66th
|
0.97
82nd
|
Liquidity (latest quarter)
7 measures| Measure | TECH | BMRN | MDGL |
|---|---|---|---|
| Cash & short-term investments | $264.7M
32nd
|
$874.0M
79th
|
$838.8M
77th
|
| Net cash (− = net debt) | −$24.4M
20th
|
−$3.3B
1st
|
$491.0M
69th
|
| Working capital | $580.7M
61st
|
$2.3B
93rd
|
$825.0M
76th
|
| Current ratio | 4.55
41st
|
2.39
12th
|
3.20
24th
|
| Quick ratio | 3.35
32nd
|
1.32
2nd
|
2.94
23rd
|
| Cash ratio (cash + ST investments / current liabilities) | 1.62
17th
|
0.53
1st
|
2.24
28th
|
| Defensive interval (days) | 324 days
20th
|
307 days
17th
|
251 days
8th
|
Leverage & solvency (latest quarter)
13 measures| Measure | TECH | BMRN | MDGL |
|---|---|---|---|
| Total debt | $289.1M
74th
|
$4.2B
99th
|
$347.8M
76th
|
| Debt / equity | 0.14
47th
|
0.66
74th
|
0.66
74th
|
| Net debt / equity | 0.01
84th
|
0.53
93rd
|
−0.94
31st
|
| Debt / assets | 10.8%
46th
|
35.8%
75th
|
27.9%
68th
|
| Debt / capital | 12.1%
47th
|
39.9%
74th
|
39.9%
74th
|
| Debt / EBITDA | 0.84
50th
|
10.90
88th
|
— |
| Net debt / EBITDA | 0.07
74th
|
8.63
93rd
|
— |
| Interest coverage (EBIT / interest) | 45.5x
91st
|
2.8x
68th
|
−9.3x
27th
|
| Cash interest coverage | 54.0x
90th
|
10.3x
77th
|
−6.3x
33rd
|
| Debt payback (years of OCF) | 1.0 yrs
51st
|
4.9 yrs
80th
|
— |
| Liabilities / assets | 21.3%
32nd
|
46.1%
60th
|
57.9%
70th
|
| IS credit model rating | AAA | BB+ | BBB+ |
| Implied credit spread (bps) | 50
0th
|
400
63rd
|
225
46th
|
Efficiency
11 measures| Measure | TECH | BMRN | MDGL |
|---|---|---|---|
| Asset turnover | 0.46
62nd
|
0.36
50th
|
1.14
97th
|
| Fixed asset turnover | 4.06
45th
|
3.44
43rd
|
74.78
93rd
|
| Inventory turnover | 2.2
46th
|
0.5
5th
|
1.3
35th
|
| Receivables turnover | 5.7
47th
|
3.6
27th
|
9.5
74th
|
| Days sales outstanding | 64 days
56th
|
103 days
75th
|
39 days
30th
|
| Days inventory outstanding | 169 days
54th
|
684 days
95th
|
272 days
65th
|
| Days payables outstanding | 23 days
6th
|
157 days
48th
|
121 days
42nd
|
| Cash conversion cycle (days) | 210 days
82nd
|
630 days
99th
|
189 days
80th
|
| Capex / revenue | 2.4%
58th
|
3.5%
68th
|
0.7%
30th
|
| Capex / depreciation | 0.30
45th
|
0.78
72nd
|
5.65
98th
|
| Operating expense ratio | 42.7%
11th
|
68.3%
28th
|
104.5%
50th
|
Cash flow & earnings quality
7 measures| Measure | TECH | BMRN | MDGL |
|---|---|---|---|
| Operating cash flow / net income | 1.61
76th
|
11.75
100th
|
— |
| FCF / net income | 1.45
73rd
|
10.12
100th
|
— |
| FCF / operating cash flow | 90.1%
38th
|
86.1%
28th
|
— |
| Capex / operating cash flow | 9.9%
62nd
|
13.9%
72nd
|
— |
| Accruals ratio | -4.2%
58th
|
-8.2%
37th
|
-11.3%
27th
|
| Sloan accruals ratio | 1.9%
46th
|
-10.1%
23rd
|
1.5%
45th
|
| Earnings quality score (0-1) | 1.00
81st
|
0.75
38th
|
— |
Scores & forensic checks
15 measures| Measure | TECH | BMRN | MDGL |
|---|---|---|---|
| IS score | 70
85th
|
47
65th
|
40
56th
|
| IS profitability | 61
79th
|
32
68th
|
20
10th
|
| IS growth | 56
45th
|
29
19th
|
59
48th
|
| IS value | 43
79th
|
44
80th
|
32
21st
|
| IS momentum | 85
89th
|
62
52nd
|
56
46th
|
| IS risk (safety) | 100
52nd
|
50
37th
|
100
52nd
|
| IS quality | 83
90th
|
64
78th
|
37
26th
|
| IS balance sheet | 83
63rd
|
50
37th
|
53
38th
|
| IS earnings quality | 73
94th
|
59
73rd
|
45
45th
|
| IS cash flow | 76
88th
|
68
82nd
|
30
8th
|
| Piotroski F-score (0-9) | 7
89th
|
4
33rd
|
2
4th
|
| Altman Z-score | 13.3
82nd
|
1.9
37th
|
11.6
79th
|
| Beneish M-score | −3.30
19th
|
−2.26
53rd
|
−0.17
79th
|
| Ohlson O-score | −10.48
10th
|
−8.12
24th
|
−5.83
54th
|
| IS credit score | 97
96th
|
50
37th
|
61
44th
|
Size (TTM)
8 measures| Measure | TECH | BMRN | MDGL |
|---|---|---|---|
| Market cap | $11.4B
88th
|
$10.6B
88th
|
$10.4B
87th
|
| Revenue | $1.2B
87th
|
$3.4B
94th
|
$1.3B
88th
|
| EBITDA | $343.4M
89th
|
$385.7M
90th
|
−$292.1M
15th
|
| Net income | $181.9M
84th
|
$73.0M
78th
|
−$325.1M
14th
|
| Free cash flow | $263.2M
88th
|
$738.2M
92nd
|
−$206.3M
24th
|
| Total assets | $2.7B
88th
|
$11.7B
98th
|
$1.2B
74th
|
| Shareholders' equity | $2.1B
91st
|
$6.3B
96th
|
$523.7M
60th
|
| Employees | 3,000
94th
|
3,221
96th
|
915
80th
|
Price performance
9 measures| Measure | TECH | BMRN | MDGL |
|---|---|---|---|
| 1 day | +0.1% | −2.4% | −2.2% |
| 1 week | +0.1% | −0.2% | −4.7% |
| 1 month | +0.2% | −16.0% | −15.8% |
| 3 months | +1.3% | −7.5% | −16.0% |
| 6 months | +22.5% | +0.1% | −15.5% |
| Year to date | +21.8% | −8.0% | −24.3% |
| 1 year | +22.0% | +3.0% | +3.8% |
| 3 years, cumulative | +5.9% | −38.3% | +223.7% |
| 5 years, cumulative | −38.3% | −29.7% | +456.7% |
Technicals
4 measures| Measure | TECH | BMRN | MDGL |
|---|---|---|---|
| RSI 14 | 58.4 | 31.4 | 24.7 |
| From 52-week high | −0.2% | −23.0% | −26.9% |
| From 52-week low | +68.3% | +11.0% | +14.3% |
| Beta | 1.29 | 0.22 | -1.05 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17